2013
DOI: 10.1111/pbi.12137
|View full text |Cite
|
Sign up to set email alerts
|

Characterization of VRC01, a potent and broadly neutralizing anti‐HIV mAb, produced in transiently and stably transformed tobacco

Abstract: SummaryThe proposed clinical trial in Africa of VRC01, a potent broadly neutralizing antibody (bNAb) capable of neutralizing 91% of known HIV‐1 isolates, raises concerns about testing a treatment which will be too expensive to be accessible by the most important target population, the poor in under‐developed regions such as sub‐Saharan Africa. Here, we report the expression of VRC01 in plants as an economic alternative to conventional mammalian‐cell‐based production platforms. The heavy and light chain genes o… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

5
52
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 45 publications
(57 citation statements)
references
References 55 publications
5
52
0
Order By: Relevance
“…Arabidopsis and Carrot [35] Human papilloma virus (HPV) HPV16-L1 Tobacco [36] HPVL1 VLPs Tomato [37] Influenza H3N2 Nucleoprotein Maize [38] Rabies G protein Maize [39] Tomato [40] Polio VP1 Tobacco and Lettuce [41] PV3 VLPs Tobacco [42] Ebola Ebola Immune Complex Tobacco [43] Antibodies Dengue E60 Tobacco [44] Human Immunodeficiency Virus (HIV) VRC01, P2G12 Tobacco [45,46] Rabies E559 Tobacco [47] 62-71-3 Tobacco [48] Single-chain antibody molecule (62-71-3) Tobacco [49] Ebola ZMapp Tobacco [50] Influenza KPF1-Antx Tobacco [51] Porcine epidemic diarrhea virus (PEDV) 2C10 Tobacco and Lettuce [52] Chikungunya CHKVmab Tobacco [53] West Nile Virus pE16 Tobacco [54] Many biopharmaceutical companies have shifted their momentum towards the plant expression system by knowing its importance. Various plants such as tobacco, duckweed, moss, alfalfa, and other plants have been used for the production of plant-made pharmaceuticals.…”
Section: Hepatitis B Surface Antigen (Hbsag)mentioning
confidence: 99%
“…Arabidopsis and Carrot [35] Human papilloma virus (HPV) HPV16-L1 Tobacco [36] HPVL1 VLPs Tomato [37] Influenza H3N2 Nucleoprotein Maize [38] Rabies G protein Maize [39] Tomato [40] Polio VP1 Tobacco and Lettuce [41] PV3 VLPs Tobacco [42] Ebola Ebola Immune Complex Tobacco [43] Antibodies Dengue E60 Tobacco [44] Human Immunodeficiency Virus (HIV) VRC01, P2G12 Tobacco [45,46] Rabies E559 Tobacco [47] 62-71-3 Tobacco [48] Single-chain antibody molecule (62-71-3) Tobacco [49] Ebola ZMapp Tobacco [50] Influenza KPF1-Antx Tobacco [51] Porcine epidemic diarrhea virus (PEDV) 2C10 Tobacco and Lettuce [52] Chikungunya CHKVmab Tobacco [53] West Nile Virus pE16 Tobacco [54] Many biopharmaceutical companies have shifted their momentum towards the plant expression system by knowing its importance. Various plants such as tobacco, duckweed, moss, alfalfa, and other plants have been used for the production of plant-made pharmaceuticals.…”
Section: Hepatitis B Surface Antigen (Hbsag)mentioning
confidence: 99%
“…Broadly neutralizing antibodies (bNAbs) are a rare class of antibodies that can develop in 15%-25% of people years after the original exposure (Teh et al, 2014). Most bNAbs show effective activity against HIV virus by disrupting viral replication via immune exclusion or through Fc-mediated antibody activities (Overbaugh and Morris, 2012).…”
Section: Broadly Neutralizing Antibodiesmentioning
confidence: 99%
“…Most bNAbs show effective activity against HIV virus by disrupting viral replication via immune exclusion or through Fc-mediated antibody activities (Overbaugh and Morris, 2012). In the case of HIV-1 infection, evidence from experimental animal models demonstrates that bNAbs can inhibit HIV-1 acquisition (Teh et al, 2014). During recent years, the monoclonal antibody therapeutics market has grown significantly, that is it increased from $50 billion in 2010 to nearly $90 billion in 2015, and this growth is predicted to reach approximately $150 billion by 2021 (https://www.reportbuyer.c om/product/5122216).…”
Section: Broadly Neutralizing Antibodiesmentioning
confidence: 99%
“…VRC01 is one of the most well-studied bNAbs, and has previously been shown to be safe and effective in humans (Ledgerwood et al, 2015;Lynch et al, 2015). Furthermore, it has previously been effectively expressed to a high degree in N. benthamiana by us and other groups (Hamorsky et al, 2019;submitted;Rosenberg et al, 2013;Teh et al, 2014). To produce this molecule, we employed the GENEWARE â transient expression vector derived from the 30B tobacco mosaic virus (TMV) vector (Shivprasad et al, 1999), which allows for the robust production of foreign proteins in N. benthamiana leaf tissue.…”
Section: Introductionmentioning
confidence: 99%